Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Harvard Business School
Federal Trade Commission
Baxter
Queensland Health
Cipla

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,211,879

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,211,879
Title:Cationic steroid antimicrobial compositions and methods of use
Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
Inventor(s): Savage; Paul B. (Mapleton, UT), Leung; Donald (Englewood, CO)
Assignee: Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO)
Application Number:12/876,993
Patent Claims:see list of patent claims

Details for Patent 8,211,879

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05 ➤ Sign Up Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16 ➤ Sign Up Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16 ➤ Sign Up Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Citi
Argus Health
Queensland Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.